Novartis CEO projects 2026 growth despite ‘largest patent expiry’ in company history Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter

#Novartis #VasNarasimhan #patentexpirations #patentcliff #Entresto #Pluvicto #Kisqali #BTKinhibitors #PSMAtargetedradioligandtherapy #prostatecancer #BTKinhibitor #chronicspontaneousurticaria #multiplesclerosis #Rhapsido #relapsingMS #MS #antibodies #Bcellpathways #Kesimpta
zurl.co/n0N8z

When Entresto’s US patent expired, the world blinked.
China didn’t.
It had already cracked the gate wide open — with filings, fights, and full-on pharma warfare. #Entresto #Novartis #ChinaPharma #GenericDrugs
Inside the siege:

www.citynewsservice.cn/news/Novarti...

Key Meeting + Program Updates All PDAB meetings will now begin at 8:00 AM (starting Aug 20) One board member shared a conflict due to owning pharmacies Ralph Magrish left his role as Executive Director. The search is on for a new leader: deadline to apply is July 28 Applications for a new PDAB member have closed and are under review

Affordability Review Discussion Migraine meds: Ajovy, Emgality, Nurtec, Ubrelvy Differences in how they work and how they’re given Prior approvals are often required (which can delay treatment)

Affordability Review Discussion Continued Vraylar: Used a lot by Medicaid patients for schizophrenia Entresto: A heart failure drug with no alternative Worries about higher prices hurting people of color Some say it’s already affordable with help programs

Looking Ahead Next PDAB Meeting: August 20, 2025 @ 8 AM Focus on migraine drugs first Board packets will be clearer, with key info up front Board wants better ways to define “affordability”

In this week's meeting, the #Oregon Prescription Drug Affordability Board (#PDAB) focused on program changes their first drug #AffordabilityReviews. Learn more in the slides →
Next meeting: August 20, 2025 @ 8 AM.
#HealthPolicySky #Migraines #Ajovy #Emgality #Nurtec #Ubrelvy #Vraylar #Entresto #OCAP

Novartis fails to block MSN from selling generic heart drug Entresto Investing.com -- A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto. U.S. District Judge Evelyn Padin in Newark, New Jersey reversed her previous ruling that had favored Novartis in its trade dress infringement claim against MSN. MSN plans to market its generic version under the name Novadoz, which combines elements of Novartis and its Sandoz (SIX:SDZ) generics division names. In her Tuesday decision, Judge Padin stated that Novartis’ exclusivity over Entresto should not continue indefinitely, adding that "denial of injunctive relief and the availability of a generic alternative to a life-savings medication is in the public interest." The judge noted that Novartis’ patent-related exclusivity for Entresto expires today, July 16.

Click Subscribe #Novartis #Entresto #GenericDrugs #Pharmaceuticals #Healthcare

#novartis #msn-pharmaceuticals #pentleasing #entresto #generic-drug #blockbuster-drug #heart-medication #drug-patent-litigation #federal-judge #preliminary-injunction #pharmaceutical-industry #ip-litigation #patent-infringement #drug-approval

Do you take or have you taken: Entresto? Generic: Sacubitril; Valsartan. Therapy Class: Cardiovascular agents – misc. Consider sharing your story with the Oregon Prescription Drug Affordability Board on July 16.

The OR PDAB is reviewing high-cost drugs that may strain OR patients or our healthcare system. PDAB’s 1st Review Will Be Of: Vraylar (Cariprazine HCl) Entresto (Sacubitril; Valsartan) Ajovy (Fremanezumab-vfrm) Emgality (Galcanezumab-gnlm) Nurtec (Rimegepant/ rimegepant sulfate) Ubrelvy (Ubrogepant)

Your Voice Matters! If you have taken any of these medications consider sharing your story at the July 16 PDAB meeting How to Share Your Experience Submit a comment - by July 14 at 9AM Speak at the meeting - sign up by July 15 at 9AM

The Oregon Prescription Drug Affordability Board is reviewing #Entresto (Generic: #Sacubitril , #Valsartan) on July 16 starting at 9 AM.

If you or someone you know has taken this medication, consider sharing your experience. Public comment: dfr.oregon.gov/pdab/Pages/p...

#OCAP #HealthPolicy

Chronic Heart Failure Market Projected to Surge with 10% CAGR by 2034 Due to Innovative Therapies The chronic heart failure market is expected to expand at a 10% CAGR until 2034, driven by the adoption of Entresto and new therapies, reshaping treatment landscapes.

Chronic Heart Failure Market Projected to Surge with 10% CAGR by 2034 Due to Innovative Therapies #USA #Las_Vegas #Chronic_Heart_Failure #Entresto #SGLT2_Inhibitors

💊 #Novartis joue avec le système des brevets pour maximiser ses gains et écarter la concurrence des génériques. 25 plaintes déposées aux #USA pour protéger son #médicament #Entresto. 🤑 Enquête🔎👉
www.publiceye.ch/fr/thematiqu...

Missbräuchliche Patente behindern Konkurrenz bei den Arzneimittelpreisen Die Schweizer Pharmakonzerne fallen auf internationaler Ebene oft durch zahlreiche Rechtsstreitigkeiten auf, die darauf abzielen, die Konkurrenz durch Generika auszuschalten und die Preise für ihre wi...

💊 #Novartis missbraucht das Patentsystem, um die Gewinne zu maximieren und die Konkurrenz durch Generika zu verdrängen. Der Multi hat in den #USA 25 Klagen eingereicht, um sein Medikament #Entresto zu schützen. 🤑
Neuer Bericht👉 www.publiceye.ch/de/themen/ph...